Trial of Male Circumcision: HIV, Sexually Transmitted Disease (STD) and Behavioral Effects in Men, Women and the Community
HIV Infections, Sexually Transmitted Diseases, Papillomavirus Infections
About this trial
This is an interventional prevention trial for HIV Infections focused on measuring HIV, STDs, Male circumcision, HIV+ males, HIV-negative males, Female partners, STDs such as the following:, HPV, HSV-2, HIV Seronegativity
Eligibility Criteria
Inclusion Criteria: MALES randomized to circumcision: Age 15-49 Able and willing to provide written informed consent Have no medical contraindications to male circumcision FEMALE partners: Able and willing to provide written informed consent No age limit Exclusion Criteria: Medical contraindications, including penile pathology or anemia (males). Unable or unwilling to provide informed consent. Please note: for participants under age 18, the study follows informed consent/assent procedures as required under US Federal Regulations. The latter are also consistent with Ugandan policy.
Sites / Locations
- Rakai Health Sciences Program
Arms of the Study
Arm 1
Arm 2
Active Comparator
No Intervention
Arm 1 Male circumcision
Arm 2
Men receive circumcision after randomization; procedure is generally provided within two weeks. A man randomized to the intervention arm who then declines circumcision for 6 or more months is considered a cross over.
Men wait for two years of follow up before being offered male circumcision